KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBT Margin: 2017-2025

Historic EBT Margin for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to -0.67%.

  • Amneal Pharmaceuticals' EBT Margin fell 286.00% to -0.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.34%, marking a year-over-year increase of 693.00%. This contributed to the annual value of -1.97% for FY2024, which is 29.00% down from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' EBT Margin is -0.67%, which was down 109.33% from 7.14% recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' EBT Margin ranged from a high of 7.14% in Q2 2025 and a low of -41.61% during Q2 2022.
  • In the last 3 years, Amneal Pharmaceuticals' EBT Margin had a median value of 2.20% in 2024 and averaged -0.29%.
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by 4,812bps in 2022, then soared by 4,656bps in 2023.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' EBT Margin stood at -3.04% in 2021, then skyrocketed by 178bps to -1.26% in 2022, then slumped by 1,227bps to -13.53% in 2023, then surged by 1,143bps to -2.10% in 2024, then plummeted by 286bps to -0.67% in 2025.
  • Its EBT Margin was -0.67% in Q3 2025, compared to 7.14% in Q2 2025 and 5.39% in Q1 2025.